CD3ε-Binding Polypeptide Variants for Affinity and Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for anti-CD3ε antibodies with diverse binding affinities and cross-reactivity to enhance therapeutic efficacy and safety, particularly for human and cynomolgus monkey applications, as existing antibodies like SP-34 are limited in variability.
Innovation Solution
Development of polypeptides comprising specific light and heavy chain variable domains that form antigen-binding domains targeting CD3ε, including single-chain and multi-chain configurations, along with anti-idiotypic antibodies, nucleic acids encoding these polypeptides, and methods for their production and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing anti-CD3ε antibodies like SP-34 are used, then therapeutic applications can be implemented, but binding affinity variability and cross-reactivity are limited
Solution Approach 1:
The patent segments the antibody structure into separate variable domains (VL and VH) that can be independently selected and combined from different parent antibodies. This modular approach allows creation of numerous variant combinations without requiring de novo development of each complete antibody, thus increasing binding affinity variability while managing the complexity of antibody development.
Solution Approach 2:
The patent changes the parameters of antibody variants by systematically varying the combination of VL and VH domains from different parent antibodies (e.g., SP-34, UCHT1, RPA-T1). This parameter variation approach generates diverse binding affinities and cross-reactivity profiles across multiple antibody variants without requiring complete redesign of each antibody.
2Reliability
If multiple antibody variants are developed to achieve diverse binding affinities, then therapeutic efficacy can be improved, but development complexity increases
Solution Approach 1:
The patent creates a universal platform where a limited set of parent antibody variable domains can serve multiple functions by being combined in different pairings. The same VL domain from one parent antibody can pair with multiple different VH domains to generate variants with different binding characteristics, reducing development complexity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses copying by selecting and recombining proven variable domains from well-characterized parent antibodies with known binding properties. Instead of developing entirely new antibodies, the invention copies and recombines existing functional domains to generate new variants with desired binding affinities and cross-reactivity profiles.
3Adaptability or versatility
If anti-CD3ε antibodies with human and cynomolgus monkey cross-reactivity are designed, then preclinical and clinical translation is enabled, but binding specificity may be compromised
Solution Approach 1:
The patent applies local quality by making the antigen-binding domain (the local region formed by VL-VH pairing) specifically adapted for cross-reactivity while keeping the rest of the antibody structure consistent. By carefully selecting VL and VH domains with appropriate complementarity determining regions (CDRs), the invention achieves species-specific binding precision in the antigen-binding site while maintaining overall cross-reactivity capability.
Data Source
AI summary
Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3ε). Also provided herein are anti-idiotypic antibodies that bind specifically to any of the antigen-binding domains described herein.